What makes Eversense® different?
The Eversense Long-Term CGM System, a new alternative to traditional CGM.
The Eversense Sensor
- Placed subcutaneously in the upper arm during an in-office procedure that takes just a few minutes
- Excellent accuracy for up to 3 months of wear
Accuracy not impacted by exercise or compression
The Eversense Smart Transmitter
- Calculates and transmits glucose data every 5 minutes via Bluetooth® LE
Provides on-body vibe alerts that can be felt while sleeping
Can be removed and reattached without wasting a sensor
The Eversense Mobile App
Displays real-time glucose data discreetly on the user’s mobile device or Apple Watch®
Eliminates the need to carry a separate receiver, further reducing complexity and visibility of diabetes disease state
Provides threshold, predictive, and rate of change alerts
Compatible with Android™ and iOS smartphones and tablets
How Eversense can enhance care and clinical practices.
Diabetes is a demanding condition for patients as well as providers, and Eversense is designed to help reduce these demands, while advancing care cadence and clinical practice goals.
Ensures patients return for scheduled three-month sensor insertion and follow-up
Fewer sensors and supplies required
Reimbursement opportunities for insertion, activation, and replacement
Fewer sensor errors, variability, and time spent educating and troubleshooting
- Kropff, J., Choudhary, P., Neupane, S., Barnard, K., Bain, S. C., Kapitza, C., … & DeVries, J. H. (2017). Accuracy and longevity of an implantable continuous glucose sensor in the PRECISE study: a 180-day, prospective, multicenter, pivotal trial. Diabetes Care, 40(1), 63-68. (PRECISE I).
- Christiansen MP, Kla LJ, Brazg R, et al. A Prospective Multicenter Evaluation of the Accuracy of a Novel Implanted Continuous Glucose Sensor: PRECISE II. Diabetes Technology & Therapeutics. 2018;20(3):197-206.
- Data on file. Senseonics 2018
- Beck RW, MD, Hirsch IB, Lael L, Tamborlane WV, et al. Eect of Continuous Glucose Monitoring in Well-Controlled Type 1 Diabetes. Diabetes Care. 2009 August; 32(8): 1378–1383.
- Summary of Safety and Eectiveness Data (SSED) Medical Device Databases – http://www.fda.gov.
- Lind M, Polonsky, W, Hirsch, I, et al. Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Injections – The GOLD Randomized Clinical Trial. [published online January 24, 2017]. JAMA.
- Beck R, Riddlesworth, T, Ruedy, K, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults with Type 1 Diabetes Using Injections for Insulin Delivery: The DIAMOND Randomized Clinical Trial. [published online January, 24, 2017]. JAMA.